Sema3A may, therefore, be of therapeutic value not only as an anti-inflammatory agent in autoimmune diseases and cancer, but potentially in preventing the development of heart failure by limiting adverse cardiac remodeling. The gene discussed is SEMA3A; the disease is autoimmune disease.